{
  "id": "resp_0e00e4e6e326670000693c816b6a548193827655bdb87490cc",
  "object": "response",
  "created_at": 1765572971,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_0e00e4e6e326670000693c816bd4e88193acc1e8d3f1dab740",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c816e1fe08193927f99b1bf144fa8",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12 TNBC NCT"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c8170bf30819390c0c93205f70e84",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c8175675c8193be541baf58ff6dec",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "dinaciclib veliparib NCT triple negative breast cancer CDK12"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c817831a88193bf85570bc4a22027",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c8181dde08193b9b73a818c4db996",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c8183ca648193b1f5c371d8fc3511",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c8184621c819393bdce6a6f50ed5d",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "PP-C8",
        "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81869b5c81939ea12e5b1411363d",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c818761fc8193810d0e7536d7c905",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "compound 7f",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9876424/"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c818a33208193baaf89f81cc08d2c",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c818b28dc8193807a7cd8fb24090f",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "Trial registration",
        "url": "https://pubmed.ncbi.nlm.nih.gov/25947565/"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c818cbb948193a3f3d7cfa8a736d7",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c818d30188193a5023c9297f0b17a",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://clinicaltrials.gov/show/NCT01624441"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c818e574c81938cb4560f8a4a5cda",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c818eac1081939ac7ea9de15ea90e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://clinicaltrials.gov/study/NCT01624441"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c818fe0f48193b5d2c416d57181a2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c8195a640819396f30f01afb8c32f",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c819665348193a306a3b4e3ae7c1c",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c81985344819386c390cbe1834a34",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov api v2 studies NCT01624441"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c819aa6f4819394142225e36b11a0",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c819e0e0881938e0567d5b80c8aac",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"CDK12\" inhibitor \"NCT\" breast cancer"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81a165e08193a4b067d2b8460527",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c81ab91448193ab162d6f7db89244",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81ae16b081939bda831cb77e3a2b",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c81afd0888193aa961d2a4b6f50e5",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"CDK12/13 inactivation triggers STING\" YJ1206 CT7439 NCT06600789"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81b50d00819393c9ecde5b837eb2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c81b8c01481938b42dbb6aa0fd5e3",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02101-x"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81ba570c81939762735677f51dd8",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c81bebaa88193b7156dedfbd540e6",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "NCT02",
        "url": "https://pubmed.ncbi.nlm.nih.gov/34289372/"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81c2c8088193a2916d37b97fa004",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c81c6ec7c81938446a4d0bacd419c",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "NCT06600789)",
        "url": "https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02101-x"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81cc758081938d36ed8973be75eb",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c81e2b9cc819391440bfb24d52d75",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.jci.org/articles/view/193745/sd/6"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81e486308193923855cd675d15a3",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c81e4d2348193bb2a71e732e8f0a9",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "CT7439",
        "url": "https://www.jci.org/articles/view/193745/sd/6"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81e801988193b003685f38cb4945",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c81f2b38c8193bc4d5cfc31de2841",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.jci.org/articles/view/193745"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81f4653081938b52657ae50582cc",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c81f51c9c8193acc56efdf7c447f7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "CT7439",
        "url": "https://www.jci.org/articles/view/193745"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81f7c4848193bd0473cea6b807a2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e00e4e6e326670000693c81f9ce088193971f1debb5d3e1d1",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "Dinaciclib and Epirubicin",
        "url": "https://www.centerwatch.com/clinical-trials/listings/NCT01624441/dinaciclib-and-epirubicin-hydrochloride-in-treating-patients-with-metastatic-triple-negative-breast-cancer"
      }
    },
    {
      "id": "rs_0e00e4e6e326670000693c81fce6908193acf10b2f0fcb90c6",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_0e00e4e6e326670000693c8216bdc08193addaac4ea9ce4899",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 766,
              "start_index": 606,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
            },
            {
              "type": "url_citation",
              "end_index": 1258,
              "start_index": 1205,
              "title": "\nJCI -\nCDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models\n",
              "url": "https://www.jci.org/articles/view/193745"
            },
            {
              "type": "url_citation",
              "end_index": 1659,
              "start_index": 1578,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 2280,
              "start_index": 2150,
              "title": "Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K | Breast Cancer Research",
              "url": "https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02101-x"
            },
            {
              "type": "url_citation",
              "end_index": 2679,
              "start_index": 2609,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
            },
            {
              "type": "url_citation",
              "end_index": 3227,
              "start_index": 3157,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 3708,
              "start_index": 3633,
              "title": "\n            Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 - PMC\n        ",
              "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9876424/"
            },
            {
              "type": "url_citation",
              "end_index": 4141,
              "start_index": 4071,
              "title": "A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25947565/"
            },
            {
              "type": "url_citation",
              "end_index": 4621,
              "start_index": 4551,
              "title": "Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34289372/"
            },
            {
              "type": "url_citation",
              "end_index": 5080,
              "start_index": 5004,
              "title": "\n            Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review - PMC\n        ",
              "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12390393/"
            }
          ],
          "logprobs": [],
          "text": "- **Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)**\n  - URL: `https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase`\n  - Quote snippets:\n    - “CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.”\n    - “Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.”\n    - “The clinical trial is enrolling patients with advanced solid tumors, including ovarian, breast and Ewing's Sarcoma.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase))\n\n- **JCI — CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models**\n  - URL: `https://www.jci.org/articles/view/193745`\n  - Quote snippets:\n    - “Using an orally bioavailable proteolysis-targeting chimera (PROTAC) degrader of CDK12/13, YJ1206 (20)”\n    - “a molecular glue degrader of cyclin K, CT7439, which inhibits CDK12/13, has progressed to a phase I clinical trial (ClinicalTrials.gov NCT06600789)” ([jci.org](https://www.jci.org/articles/view/193745))\n\n- **Trial | NCT06600789 — A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies**\n  - URL: `https://cdek.pharmacy.purdue.edu/trial/NCT06600789/`\n  - Quote snippets:\n    - “A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies”\n    - “CT7439 Capsules (0.5 mg, 1mg, 3mg)” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))\n\n- **Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K (Breast Cancer Research; 2025)**\n  - URL: `https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02101-x`\n  - Quote snippets:\n    - “CT7439, a dual inhibitor of CDK12/13 and a cyclin K glue degrader, is now in phase I/II clinical trial for advanced solid tumors, including breast cancer (NCT06600789).”\n    - “The cyclin K degrader CR8 is effective for the growth of TNBC cells” ([breast-cancer-research.biomedcentral.com](https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02101-x))\n\n- **Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer (Cancer Cell)**\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/31668947/`\n  - Quote snippets:\n    - “Here we report the development of SR-4835, a highly selective dual inhibitor of CDK12 and CDK13, which disables triple-negative breast cancer (TNBC) cells.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/))\n\n- **Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor (Eur J Med Chem)**\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/34864331/`\n  - Quote snippets:\n    - “we have synthesized a potent PROTAC degrader PP-C8 based on the noncovalent dual inhibitors of CDK12/13”\n    - “PP-C8 demonstrates profound synergistic antiproliferative effects with PARP inhibitor in triple-negative breast cancer (TNBC).” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))\n\n- **Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 (ACS; full text on PMC)**\n  - URL: `https://pmc.ncbi.nlm.nih.gov/articles/PMC9876424/`\n  - Quote snippets:\n    - “The optimal compound 7f effectively degraded CDK12 and CDK13 with DC_{50} values of 2.2 and 2.1 nM, respectively”\n    - “7f markedly inhibited proliferation of multiple TNBC cell lines including MFM223” ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9876424/))\n\n- **A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer (Invest New Drugs)**\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/25947565/`\n  - Quote snippets:\n    - “dinaciclib (SCH 727965)”\n    - “Trial registration:  ClinicalTrials.gov NCT01624441.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25947565/))\n\n- **Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (Cell Reports)**\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/34289372/`\n  - Quote snippets:\n    - “NCT02 is identified as a candidate with minimal risk of non-specific toxicity.”\n    - “NCT02 acts as molecular glue that induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34289372/))\n\n- **Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review (PMC)**\n  - URL: `https://pmc.ncbi.nlm.nih.gov/articles/PMC12390393/`\n  - Quote snippets:\n    - “Selective CDK12 PROTACs include Molecule 50 (BSJ-4-116) and Molecule 51 (PP-C8)”\n    - “Representative compounds include CR8, DS17/30, compound 21195, SR-4835, HQ461, NCT02” ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12390393/))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 83524,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 10219,
    "output_tokens_details": {
      "reasoning_tokens": 8839
    },
    "total_tokens": 93743
  },
  "user": null,
  "metadata": {}
}